Systemic Embolism and Clinically Significant Bleeding Events in Older Adults with Nonvalvular Atrial Fibrillation After Treatment with Direct Oral Anticoagulants and Warfarin: A Retrospective Cohort Study in Japan

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 8

PMID 39771495

Authors

Daichi Yaguchi

Shoji Sera

Akira Okada

Yuki Nishimura

Satoshi Tamaru

Naomi Nagai

Affiliations

Soon will be listed here.

Abstract

Anticoagulant therapy, particularly the use of direct oral anticoagulant agents (DOACs), is recommended for patients with nonvalvular atrial fibrillation (NVAF). This multicenter observational retrospective cohort study aimed to assess the efficacy and safety of DOACs compared to warfarin in Japanese patients aged 75 years and older with NVAF. Data from the Mie-Life Innovation Promotion Center Database were used to collect medical information on the patients. The cumulative incidences of clinically significant bleeding events and systemic embolic events (SEEs) were analyzed. This study included 1787 older adult patients, of whom 1321 received DOACs (edoxaban: 428; apixaban: 586; dabigatran: 105; rivaroxaban: 202) and 466 receiving warfarin. There were no statistically significant differences in the cumulative incidence of bleeding events between the DOAC- and warfarin-treated groups. However, a statistically significant difference was observed for SEEs, with dabigatran showing a significantly lower incidence compared to warfarin. The incidence rates of bleeding events for individual DOACs were comparable to those for warfarin. Additionally, a history of vascular disorders was identified as a risk factor for bleeding events in the DOAC-treated group (hazard ratio (HR): 1.83, 95% confidence interval (CI): 1.16-2.88, < 0.01) and warfarin-treated group (HR: 1.80, 95% CI: 1.15-2.84, < 0.01). Based on real-world data, the overall efficacy and safety of DOACs were generally comparable to warfarin.

References

Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S . Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS. PLoS One. 2021; 16(6):e0251325. PMC: 8195353. DOI: 10.1371/journal.pone.0251325. View

Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J . Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. J Manag Care Spec Pharm. 2018; 24(11):1116-1127. PMC: 10398049. DOI: 10.18553/jmcp.2018.17488. View

Yamashita T, Koretsune Y, Nagao T, Shiosakai K . Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two-year postmarketing surveillance study (ETNA-AF-Japan). J Arrhythm. 2021; 37(2):370-383. PMC: 8021991. DOI: 10.1002/joa3.12520. View

Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun Y, Tsuji H . Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　- Fushimi AF Registry. Circ J. 2017; 81(9):1278-1285. DOI: 10.1253/circj.CJ-16-1337. View

Akao M, Ogawa H, Masunaga N, Minami K, Ishigami K, Ikeda S . 10-Year Trends of Antithrombotic Therapy Status and Outcomes in Japanese Atrial Fibrillation Patients　- The Fushimi AF Registry. Circ J. 2022; 86(4):726-736. DOI: 10.1253/circj.CJ-22-0023. View

Libby P, Ridker P, Hansson G . Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473(7347):317-25. DOI: 10.1038/nature10146. View

Wolf P, Abbott R, Kannel W . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8):983-8. DOI: 10.1161/01.str.22.8.983. View

Goto S, Zhu J, Liu L, Oh B, Wojdyla D, Aylward P . Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation.... Am Heart J. 2014; 168(3):303-9. DOI: 10.1016/j.ahj.2014.06.005. View

Yamashita T, Koretsune Y, Yang Y, Chen S, Chung N, Shimada Y . Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation　- An ENGAGE AF-TIMI 48 Subanalysis. Circ J. 2016; 80(4):860-9. DOI: 10.1253/circj.CJ-15-1082. View

10.

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

11.

Ezekowitz M, Bridgers S, James K, CARLINER N, Colling C, Gornick C . Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992; 327(20):1406-12. DOI: 10.1056/NEJM199211123272002. View

12.

Ono K, Iwasaki Y, Akao M, Ikeda T, Ishii K, Inden Y . JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circ J. 2022; 86(11):1790-1924. DOI: 10.1253/circj.CJ-20-1212. View

13.

Koretsune Y, Yamashita T, Yasaka M, Oda E, Matsubayashi D, Ota K . Usefulness of a healthcare database for epidemiological research in atrial fibrillation. J Cardiol. 2016; 70(2):169-179. DOI: 10.1016/j.jjcc.2016.10.015. View

14.

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

15.

Hori M, Connolly S, Zhu J, Liu L, Lau C, Pais P . Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013; 44(7):1891-6. DOI: 10.1161/STROKEAHA.113.000990. View

16.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

17.

Mega J, Braunwald E, Wiviott S, Bassand J, Bhatt D, Bode C . Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2011; 366(1):9-19. DOI: 10.1056/NEJMoa1112277. View

18.

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

19.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

20.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438):937-52. DOI: 10.1016/S0140-6736(04)17018-9. View